

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Composite scaffold as cell delivery platform for cardiovascular repair	<p>A composite tissue scaffold could be useful as a cell delivery platform to treat myocardial infarction (MI). The scaffold consisted of thin sheets of decellularized human myocardium injected with a hydrogel containing transforming growth factor-β (TGFB; TGFβ)-conditioned human mesenchymal progenitor cells (MPCs). In a rat model of MI, implanting the MPC scaffold into a cardiac infarct region led to the formation of new vascular networks compared with implanting the scaffold alone. Next steps include evaluating the composite scaffold in large animal models of MI.</p> <p>SciBX 4(18); doi:10.1038/scibx.2011.528 Published online May 5, 2011</p>	<p>Patent pending; available for licensing from Columbia Technology Ventures Contact: Donna See, Columbia Technology Ventures, New York, N.Y. phone: 917-512-3037 e-mail: dks26@columbia.edu</p>	<p>Godier-Furnémont, A.F.G. <i>et al.</i> <i>Proc. Natl. Acad. Sci. USA</i>; published online April 18, 2011; doi:10.1073/pnas.1104619108 Contact: Gordana Vunjak-Novakovic, Columbia University Medical Center, New York, N.Y. e-mail: gv2131@columbia.edu</p>